improvements, others reporting no effect, and some reporting worsening of pruritus.
Ivermectin versus permethrin in the treatment of scabies: A systematic review and meta-analysis of randomized controlled trials To the Editor: Scabies, an intensely pruritic ectoparasitic skin infestation, affects over 130 million people and hampers quality of life. 1, 2 Permethrin is considered the most effective topical treatment for scabies. 3 Ivermectin is the only oral alternative and can also be applied topically. Because randomized controlled trials comparing oral or topical ivermectin with topical permethrin have been inconclusive, we performed a meta-analysis.
On March 21, 2017, we searched PubMed, Embase, Cochrane Library, and references of included articles using the terms ''scabies'' and ''permethrin'' and ''ivermectin'' for peer-reviewed randomized controlled trials comparing oral or topical ivermectin with topical permethrin in patients with scabies. Two authors independently selected studies, extracted data, and assessed study quality using the Cochrane Risk of Bias Tool. The primary outcome was treatment failure as defined in the individual studies, although we required that the definition include persistent lesions, new lesions, or confirmation of a live mite. Secondary outcomes were persistence of itch and adverse effects. We calculated pooled risk ratios (RRs) and 95% confidence intervals (CIs) using a random effects model.
Our search identified 461 potential articles. We ultimately included 15 randomized controlled trials, which contained 2172 patients. Table I summarizes the main study characteristics. In terms of dose regimens, oral ivermectin (200 g/kg) was given as a single dose in 5 trials and repeat doses in 9 trials. Topical ivermectin (1%) was given as repeat applications in 2 trials. Topical permethrin (5%) was given as a single application in 5 trials and repeat applications in 9 trials, while topical permethrin (2.5%) was given as repeat applications in 1 trial.
Oral ivermectin was associated with a significantly increased risk of treatment failure compared with topical permethrin (RR (Fig 1) . Metaregression revealed no significant heterogeneity by various study characteristics: length of followup, treatment of family or close contacts, repetition of ivermectin dose, itch in definition of treatment failure, and microscopy in definition of treatment failure. Visual inspection of the funnel plot and Egger's test (P ¼ .19) revealed no 2 ¼ 0%, n ¼ 580). One trial by Chhaiya et al found no significant difference in itch persistence between both agents. 4 The number of adverse effects were few: 4.3% (26/604) for oral ivermectin, 4.6% (35/758) for topical permethrin, and 6.9% (20/291) for topical ivermectin. There were no serious adverse effects.
Several other topical treatments are available for scabies: benzyl benzoate, lindane, crotamiton, malathion, and sulfur. A previous systematic review found topical permethrin to be the most effective current scabicide. 3 Although the authors found much higher treatment failures with oral ivermectin compared with topical permethrin than in our study, the review only included two small trials (n ¼ 140) and data from the earliest follow-up visit. Indeed, several studies have noted a slower response with oral ivermectin. 5 Of note, our meta-regression analyses found no significant difference between trials using single and multiple doses of oral ivermectin (P heterogeneity ¼ .46). However, given ivermectin's limited ovicidal activity and short half-life, it would be prudent to administer 2 doses at least 4 days apart. 6 Other factors could also affect choice of agent. Ivermectin is cheaper, and oral administration might improve adherence. 5 However, oral ivermectin is not approved for use in young children and pregnant or lactating womenekey groups that most trials excluded. It should be noted that the basis for therapeutic recommendations should not be made solely on a meta-analysis. Our study was limited by the lack of patient-level data; potential performance bias (assessment of study quality revealed absence of blinding in most trials); and trial exclusion of subjects with crusted scabies, which generally requires combination therapy. Our findings, however, suggest that combination therapy with oral ivermectin and topical permethrin is presumably safe and, in typical scabies, might potentially enhance efficacy.
In summary, oral ivermectin is less effective than topical permethrin. Topical ivermectin may have a similar efficacy to topical permethrin, but further Cantharidin for treatment of facial molluscum contagiosum: A retrospective review
To the Editor: Molluscum contagiosum (MC) papules are self-limited, resolving within months to years. Active nonintervention is a common management Table I for reference information.
